← Eichor
Study identifier: NCT03291223 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Gaucher Disease Outcome Survey (GOS)

Condition: Gaucher Disease  ·  Sponsor: Shire

PhaseN/A
Planned participants1257
Who can joinAll sexes, N/A to no upper limit
Healthy volunteersNo

About this study

The Gaucher Outcomes Survey (GOS) is an ongoing observational, international, multi-center, long-term Registry of Patients with Gaucher Disease irrespective of their treatment status or type of treatment received. No experimental intervention is involved. Patients undergo clinical assessments and receive care as determined by the patients' treating physician. The objectives of the registry include to evaluate the safety and long-term effectiveness of velaglucerase alfa, to characterize patients receiving velaglucerase alfa or other Gaucher Disease-specific treatments, to gain a better understanding of the natural history of GD and to serve as a database for evidence-based management of Gaucher Disease over time in real-life clinical practice.

This description comes directly from the study's public registry record.

Talk to the study team

Shire Contact  ·  +1 866 842 5335  ·  ClinicalTransparency@shire.com

Always discuss trial participation with your own doctor first.

Locations (1)

Central ContactLexington, Massachusetts, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT03291223